Genmab | Srodki Pieniężne I Ekwiwalent



Cash And Equivalent Zmiana Data
Agios Pharmaceuticals USD 76.25M 177.48M 2024-12
Almirall EUR 329.41M 15.11M 2024-06
Amarin USD 156.94M 58.98M 2024-09
Amgen USD 11.97B 2.96B 2024-12
AstraZeneca USD 5.49B 691M 2024-12
Bayer EUR 6.19B 1.57B 2024-12
BioMarin Pharmaceutical USD 613.22M 324.54M 2024-12
Demant 1.11B 64M 2024-12
Exelixis USD 217.37M 40.97M 2025-01
Fresenius Medical Care EUR 1.18B 191M 2024-12
Galapagos EUR 64.24M 8.72M 2024-12
Genmab DKK 9.86B 3.52B 2024-12
GlaxoSmithKline GBP 3.87B 678M 2024-12
GN Store Nord DKK 688M 412M 2024-12
GRIFOLS EUR 979.78M 334.84M 2024-12
Hikma Pharmaceutical USD 0 1000K 2024-06
Insmed USD 555.03M 93.58M 2024-12
Lonza CHF 1.11B 286M 2024-12
Merck EUR 3.16B 476M 2024-09
Novartis USD 8.87B 4.74B 2024-12
Regeneron Pharmaceuticals USD 17.91B 15.9B 2024-12
Roche Holding CHF 6.98B 2.15B 2024-12
Sanofi 6.8B 1.92B 2024-06
UCB EUR 1.57B 1.14B 2024-12



Genmab Srodki Pieniężne I Ekwiwalent - Aktualne wartości, dane historyczne, prognozy, statystyki, wykresy i kalendarz ekonomiczny - Mar 2025.